An analysis of the effect of funding source in randomized clinical trials of second generation antipsychotics for the treatment of schizophrenia

Background:Medication of acute episodes of mood disorders has changed over the last decades following the results of randomized clinical trials.Objective:The aim of this study was to analyze medication prescribed at discharge from two psychiatric wards. We focused on hospitalization as one of the best opportunities to start prophylaxis.Methods:We examined retrospectively the clinical records of 357 patients hospitalized for mood episodes in two psychiatric wards in the Cagliari area (SPDC-1 and SPDC-2) between 1 January and 31 December 2016. We focused on the psychotropic medication prescribed at discharge from the hospital.Results:Most patients were discharged with antipsychotics (86%) and/or benzodiazepines (89%). Combined medication was frequent, including various co-administration of first-generation and/or second-generation antipsychotics (26% of patients), or antipsychotics combined with mood-stabilizers (51% of patients). There was a preferential prescription of first-generation antipsychotics in SPDC-1, and of second-generation antipsychotics in SPDC-2. Prescription of lithium was significantly more frequent in SPDC-1.Conclusion:Although the treatment was in line with randomized clinical trials, the choice of individual psychotropic agents differed significantly between the two wards. Different prescription attitudes can have consequences on the long-term outcome of patients discharged from the hospital after an acute mood episode.

Download Full-text

Efficacy of second-generation-antipsychotics in the treatment of negative symptoms of schizophrenia: A meta-analysis of randomized clinical trials

Revista de Psiquiatría y Salud Mental (English Edition) ◽

10.1016/j.rpsmen.2011.02.001 ◽

2011 ◽

Vol 4 (3) ◽

pp. 126-143 ◽

Cited By ~ 1

Author(s):

Josep Darbà ◽

Agnès Minoves ◽

Emilio Rojo ◽

Francesca Jimenez ◽

Javier Rejas

Keyword(s):

Clinical Trials ◽

Negative Symptoms ◽

Second Generation ◽

Randomized Clinical Trials ◽

Meta Analysis ◽

Second Generation Antipsychotics

Download Full-text

Faster onset of antimanic action with haloperidol compared to second-generation antipsychotics. A meta-analysis of randomized clinical trials in acute mania

European Neuropsychopharmacology ◽

10.1016/j.euroneuro.2012.05.017 ◽

2013 ◽

Vol 23 (4) ◽

pp. 305-316 ◽

Cited By ~ 17

Author(s):

J.M. Goikolea ◽

F. Colom ◽

J. Capapey ◽

I. Torres ◽

M. Valenti ◽

...

Keyword(s):

Clinical Trials ◽

Second Generation ◽

Randomized Clinical Trials ◽

Meta Analysis ◽

Acute Mania ◽

Second Generation Antipsychotics

Download Full-text

22.1 Can Pediatric Bipolar Disorder be Successfully Treated When Comorbid With Conduct Disorder? A Secondary Analysis of Six Clinical Trials of Second Generation Antipsychotics

Journal of the American Academy of Child & Adolescent Psychiatry ◽

10.1016/j.jaac.2021.07.825 ◽

2021 ◽

Vol 60 (10) ◽

pp. S291

Author(s):

Janet Wozniak

Keyword(s):

Bipolar Disorder ◽

Clinical Trials ◽

Conduct Disorder ◽

Second Generation ◽

Secondary Analysis ◽

Pediatric Bipolar Disorder ◽

Second Generation Antipsychotics

Download Full-text

COMPARING THE EFFECT OF SECOND-GENERATION ANTIPSYCHOTICS VERSUS SELECTIVE SEROTONIN REUPTAKE INHIBITORS IN REFRACTORY OBSESSIVE-COMPULSIVE DISORDER: A SYSTEMATIC REVIEW OF THE PAST, PRESENT, AND FUTURE CLINICAL TRIALS

Asian Journal of Pharmaceutical and Clinical Research ◽

10.22159/ajpcr.2017.v10i1.14528 ◽

2016 ◽

Vol 10 (1) ◽

pp. 150

Author(s):

Mehdi Sayah ◽

Fakher Rahim

Keyword(s):

Systematic Review ◽

Clinical Trials ◽

Early Treatment ◽

Serotonin Reuptake ◽

Selective Serotonin Reuptake Inhibitors ◽

Second Generation ◽

Treatment Programs ◽

Obsessive Compulsive ◽

Compulsive Disorder ◽

Second Generation Antipsychotics

ABSTRACTObjective: In this concise and systematic review, the trend of using major medication modalities prescribed for refractory obsessive-compulsivedisorder (OCD), including serotonin-specific reuptake inhibitors (SSRIs) and second-generation antipsychotics (SGAs) are discussed.Methods: We systematically searched PubMed and Cochrane Central Register of Controlled Trials (CENTRAL) systematically using Mesh terms. OCDis extremely disabling and associated with considerable depression and other serious psychiatric illnesses.Results: Through databases, we found 78 randomized clinical trials (RCTs), which included selective SSRI compared with routine drug therapy orplacebo. Out of these 78 studies, 62 studies were conducted on adult patients with OCD, comprising 7920 cases. While only 16 RCTs were performedon children and adolescents with OCD, including 1313 people. We found 24 clinical trial studies related to SGAs, of which were conducted on adultpatients with OCD, including 992 cases.Conclusion: As our data showed among the SSRIs, fluvoxamine has been particularly well studied and used in RCTs in both children and adolescents withOCD. According to the summary of our review, it will be better when therapists use SGAs in the early treatment programs of refractory OCD. Thus, consideringour reviewed, it seems that the first choice of early treatment programs of refractory OCD is fluvoxamine in combination with quetiapine or aripiprazole.Keywords: Obsessive-compulsive disorder, Refractory, Second-generation antipsychotic drugs, Selective serotonin reuptake inhibitors.

Download Full-text